<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39339646</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Impact of Omega-3 Fatty Acid Supplementation in Parenteral Nutrition on Inflammatory Markers and Clinical Outcomes in Critically Ill COVID-19 Patients: A Randomized Controlled Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3046</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu16183046</ELocationID><Abstract><AbstractText>The heightened inflammatory response observed in COVID-19 patients suggests that omega-3 fatty acids (O3FA) may confer anti-inflammatory benefits. This randomized, double-blind, single-center clinical trial aimed to evaluate the effect of O3FA supplementation in parenteral nutrition (PN) on inflammatory markers in COVID-19 patients admitted to the intensive care unit (ICU). A total of 69 patients were randomized into three groups: one received standard lipid emulsion, and two received O3FA (Omegaven<sup>®</sup>) at doses of 0.1 g/kg/day and 0.2 g/kg/day, respectively, in addition to Smoflipid<sup>®</sup>. The primary outcomes measured were serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) on days 1, 5, and 10 of PN initiation. Secondary outcomes included additional inflammatory markers (TNF-α, IFN-γ, IL-1Ra, CXCL10), hepatic function, triglyceride levels, and clinical outcomes such as mortality and length of ICU and hospital stay. Results indicated a significant reduction in CRP, IL-6, and CXCL10 levels in the group receiving 0.1 g/kg/day O3FA compared to the control. Additionally, the higher O3FA dose was associated with a shorter ICU and hospital stay. These findings suggest that O3FA supplementation in PN may reduce inflammation and improve clinical outcomes in critically ill COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berlana</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5772-7284</Identifier><AffiliationInfo><Affiliation>Pharmacy Department, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology, Toxicology and Therapeutic Chemistry Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albertos</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barquin</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biochemistry Department, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pau-Parra</LastName><ForeName>Alba</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9773-8690</Identifier><AffiliationInfo><Affiliation>Pharmacy Department, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díez-Poch</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Martínez</LastName><ForeName>Rocío</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8304-7194</Identifier><AffiliationInfo><Affiliation>Immunology Department, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cea</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biochemistry Department, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantenys-Molina</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Immunology Department, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer-Costa</LastName><ForeName>Roser</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8925-3172</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemical Chemistry, Drug Delivery &amp; Therapy (BC-DDT) Research Group, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010288" MajorTopicYN="Y">Parenteral Nutrition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="Y">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="Y">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C-reactive protein</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">fish oil</Keyword><Keyword MajorTopicYN="N">immunomodulation</Keyword><Keyword MajorTopicYN="N">inflammatory markers</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">omega-3 fatty acids</Keyword><Keyword MajorTopicYN="N">parenteral nutrition</Keyword></KeywordList><CoiStatement>D. Berlana has received consultant fees and speaker’s honoraria from Baxter and Fresenius Kabi.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339646</ArticleId><ArticleId IdType="pmc">PMC11434828</ArticleId><ArticleId IdType="doi">10.3390/nu16183046</ArticleId><ArticleId IdType="pii">nu16183046</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.J.A., Ribeiro L.R., Gouveia M.I.M., Marcelino B.d.R., Santos C.S.d., Lima K.V.B., Lima L.N.G.C. Hyperinflammatory Response in COVID-19: A Systematic Review. Viruses. 2023;15:553. doi: 10.3390/v15020553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020553</ArticleId><ArticleId IdType="pmc">PMC9962879</ArticleId><ArticleId IdType="pubmed">36851766</ArticleId></ArticleIdList></Reference><Reference><Citation>Batah S.S., Fabro A.T. Pulmonary Pathology of ARDS in COVID-19: A Pathological Review for Clinicians. Respir. Med. 2021;176:106239. doi: 10.1016/j.rmed.2020.106239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106239</ArticleId><ArticleId IdType="pmc">PMC7674971</ArticleId><ArticleId IdType="pubmed">33246294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Haagmans B.L. SARS-CoV-2 Pathogenesis. Nat. Rev. Microbiol. 2022;20:270–284. doi: 10.1038/s41579-022-00713-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar M., Sandulescu M., Barbu E.C., Chitu-Tisu C.E., Andreescu D.I., Anton A.N., Erculescu T.M., Petre A.M., Duca G.T., Simion V., et al. The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)View. Biomedicines. 2024;12:639. doi: 10.3390/biomedicines12030639.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12030639</ArticleId><ArticleId IdType="pmc">PMC10968428</ArticleId><ArticleId IdType="pubmed">38540252</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley C.D., Gilroy D.W., Serhan C.N. Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. Immunity. 2014;40:315–327. doi: 10.1016/j.immuni.2014.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.02.009</ArticleId><ArticleId IdType="pmc">PMC4004957</ArticleId><ArticleId IdType="pubmed">24656045</ArticleId></ArticleIdList></Reference><Reference><Citation>Basil M.C., Levy B.D. Specialized Pro-Resolving Mediators: Endogenous Regulators of Infection and Inflammation. Nat. Rev. Immunol. 2016;16:51–67. doi: 10.1038/nri.2015.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2015.4</ArticleId><ArticleId IdType="pmc">PMC5242505</ArticleId><ArticleId IdType="pubmed">26688348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T., Yoshida M., Arita M. Omega-3 Fatty Acid-Derived Mediators That Control Inflammation and Tissue Homeostasis. Int. Immunol. 2019;31:559–567. doi: 10.1093/intimm/dxz001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxz001</ArticleId><ArticleId IdType="pubmed">30772915</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutiérrez S., Svahn S.L., Johansson M.E. Effects of Omega-3 Fatty Acids on Immune Cells. Int. J. Mol. Sci. 2019;20:5028. doi: 10.3390/ijms20205028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205028</ArticleId><ArticleId IdType="pmc">PMC6834330</ArticleId><ArticleId IdType="pubmed">31614433</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrinhas R.S., Calder P.C., Lemos G.O., Waitzberg D.L. Parenteral Fish Oil: An Adjuvant Pharmacotherapy for Coronavirus Disease 2019? Nutrition. 2021;81:110900. doi: 10.1016/j.nut.2020.110900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2020.110900</ArticleId><ArticleId IdType="pmc">PMC7836308</ArticleId><ArticleId IdType="pubmed">32738510</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder P.C. Marine Omega-3 Fatty Acids and Inflammatory Processes: Effects, Mechanisms and Clinical Relevance. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2015;1851:469–484. doi: 10.1016/j.bbalip.2014.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2014.08.010</ArticleId><ArticleId IdType="pubmed">25149823</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev E., Sarapultsev A., Solomatina L., Chereshnev V. Sars-Cov-2-Specific Immune Response and the Pathogenesis of COVID-19. Int. J. Mol. Sci. 2022;23:1716. doi: 10.3390/ijms23031716.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031716</ArticleId><ArticleId IdType="pmc">PMC8835786</ArticleId><ArticleId IdType="pubmed">35163638</ArticleId></ArticleIdList></Reference><Reference><Citation>Barazzoni R., Bischoff S.C., Breda J., Wickramasinghe K., Krznaric Z., Nitzan D., Pirlich M., Singer P. ESPEN Expert Statements and Practical Guidance for Nutritional Management of Individuals with SARS-CoV-2 Infection. Clin. Nutr. 2020;39:1631–1638. doi: 10.1016/j.clnu.2020.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.03.022</ArticleId><ArticleId IdType="pmc">PMC7138149</ArticleId><ArticleId IdType="pubmed">32305181</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer P., Blaser A.R., Berger M.M., Alhazzani W., Calder P.C., Casaer M.P., Hiesmayr M., Mayer K., Montejo J.C., Pichard C., et al. ESPEN Guideline on Clinical Nutrition in the Intensive Care Unit. Clin. Nutr. 2019;38:48–79. doi: 10.1016/j.clnu.2018.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2018.08.037</ArticleId><ArticleId IdType="pubmed">30348463</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder P.C., Adolph M., Deutz N.E., Grau T., Innes J.K., Klek S., Lev S., Mayer K., Michael-Titus A.T., Pradelli L., et al. Lipids in the Intensive Care Unit: Recommendations from the ESPEN Expert Group. Clin. Nutr. 2018;37:1–18. doi: 10.1016/j.clnu.2017.08.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2017.08.032</ArticleId><ArticleId IdType="pubmed">28935438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradelli L., Klek S., Mayer K., Omar Alsaleh A.J., Rosenthal M.D., Heller A.R., Muscaritoli M. Omega-3 Fatty Acid-Containing Parenteral Nutrition in ICU Patients: Systematic Review with Meta-Analysis and Cost-Effectiveness Analysis. Crit. Care. 2020;24:634. doi: 10.1186/s13054-020-03356-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03356-w</ArticleId><ArticleId IdType="pmc">PMC7607851</ArticleId><ArticleId IdType="pubmed">33143750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradelli L., Mayer K., Klek S., Rosenthal M.D., Povero M., Heller A.R., Muscaritoli M. Omega-3 Fatty Acids in Parenteral Nutrition—A Systematic Review with Network Meta-Analysis on Clinical Outcomes. Clin. Nutr. 2023;42:590–599. doi: 10.1016/j.clnu.2023.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2023.02.008</ArticleId><ArticleId IdType="pubmed">36878111</ArticleId></ArticleIdList></Reference><Reference><Citation>Velotti F., Costantini L., Merendino N. Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) for Immunomodulation in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) J. Clin. Med. 2023;12:304. doi: 10.3390/jcm12010304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12010304</ArticleId><ArticleId IdType="pmc">PMC9820910</ArticleId><ArticleId IdType="pubmed">36615103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungurtekin H., Deǧirmenci S., Sungurtekin U., Oguz B.E., Sabir N., Kaptanoglu B. Comparison of the Effects of Different Intravenous Fat Emulsions in Patients with Systemic Inflammatory Response Syndrome and Sepsis. Nutr. Clin. Pract. 2011;26:665–671. doi: 10.1177/0884533611418783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0884533611418783</ArticleId><ArticleId IdType="pubmed">22205554</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel R.F.W., Silva A.P., Santana A.I.C., Silva D.d.S.e., Ramos M.d.S., de Souza M.C., Suen V.M.M., Maduro I.P.d.N.N., Filho D.R., Júnior A.D., et al. Effect of Immunonutrition on Serum Levels of C-Reactive Protein and Lymphocytes in Patients with COVID-19: A Randomized, Controlled, Double-Blind Clinical Trial. Nutr. Hosp. 2022;39:20–26. doi: 10.20960/nh.03847.</Citation><ArticleIdList><ArticleId IdType="doi">10.20960/nh.03847</ArticleId><ArticleId IdType="pubmed">34839672</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedighiyan M., Abdollahi H., Karimi E., Badeli M., Erfanian R., Raeesi S., Hashemi R., Vahabi Z., Asanjarani B., Mansouri F., et al. Omega-3 Polyunsaturated Fatty Acids Supplementation Improve Clinical Symptoms in Patients with Covid-19: A Randomised Clinical Trial. Int. J. Clin. Pract. 2021;75:e14854. doi: 10.1111/ijcp.14854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14854</ArticleId><ArticleId IdType="pubmed">34516692</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman O.M., Abbas Y.H., Aboelhassan A.M.A., Ismail E.A. Could Early Infusion of Fish-Oil-Based Lipid Emulsion Affect the Need for Intensive Care in Moderately Diseased COVID-19 Patients? A Randomized Clinical Trial. Ain-Shams J. Anesthesiol. 2022;14:54. doi: 10.1186/s42077-022-00251-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42077-022-00251-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmopoulos A., Bhatt D.L., Meglis G., Verma R., Pan Y., Quan A., Teoh H., Verma M., Jiao L., Wang R., et al. A Randomized Trial of Icosapent Ethyl in Ambulatory Patients with COVID-19. iScience. 2021;24:103040. doi: 10.1016/j.isci.2021.103040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103040</ArticleId><ArticleId IdType="pmc">PMC8388138</ArticleId><ArticleId IdType="pubmed">34462732</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha A.M., Shaarawy A.S., Omar M.M., Abouelmagd K., Shalma N.M., Alhashemi M., Ahmed H.M., Allam A.H., Abd-ElGawad M. Effect of Omega-3 Fatty Acids Supplementation on Serum Level of C-Reactive Protein in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Transl. Med. 2022;20:401. doi: 10.1186/s12967-022-03604-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03604-3</ArticleId><ArticleId IdType="pmc">PMC9444081</ArticleId><ArticleId IdType="pubmed">36064554</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue H.-Y., Zeng J., Wang Y., Deng M.J., Peng W., Tan X., Jiang H. Efficacy of Omega-3 Fatty Acids for Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Asia Pac. J. Clin. Nutr. 2023;32:308–320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11090385</ArticleId><ArticleId IdType="pubmed">37789651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Su S., Wang C., Hu J., Dan W., Peng X. Effects of Fish Oil-Containing Nutrition Supplementation in Adult Sepsis Patients: A Systematic Review and Meta-Analysis. Burns Trauma. 2022;10:tkac012. doi: 10.1093/burnst/tkac012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/burnst/tkac012</ArticleId><ArticleId IdType="pmc">PMC9185164</ArticleId><ArticleId IdType="pubmed">35702267</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnardottir H., Pawelzik S., Sarajlic P., Quaranta A., Kolmert J., Religa D., Wheelock C.E., Bäck M. Immunomodulation by Intravenous Omega-3 Fatty Acid Treatment in Older Subjects Hospitalized for COVID-19: A Single-blind Randomized Controlled Trial. Clin. Transl. Med. 2022;12:e895. doi: 10.1002/ctm2.895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.895</ArticleId><ArticleId IdType="pmc">PMC9484265</ArticleId><ArticleId IdType="pubmed">36121173</ArticleId></ArticleIdList></Reference><Reference><Citation>Doaei S., Gholami S., Rastgoo S., Gholamalizadeh M., Bourbour F., Bagheri S.E., Samipoor F., Akbari M.E., Shadnoush M., Ghorat F., et al. The Effect of Omega-3 Fatty Acid Supplementation on Clinical and Biochemical Parameters of Critically Ill Patients with COVID-19: A Randomized Clinical Trial. J. Transl. Med. 2021;19:128. doi: 10.1186/s12967-021-02795-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-02795-5</ArticleId><ArticleId IdType="pmc">PMC8006115</ArticleId><ArticleId IdType="pubmed">33781275</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Wang D., Wei H., Xu X. Cytokine Storm and Translating IL-6 Biology into Effective Treatments for COVID-19. Front. Med. 2023;17:1080–1095. doi: 10.1007/s11684-023-1044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-023-1044-4</ArticleId><ArticleId IdType="pubmed">38157195</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlana D. Parenteral Nutrition Overview. Nutrients. 2022;14:4480. doi: 10.3390/nu14214480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14214480</ArticleId><ArticleId IdType="pmc">PMC9659055</ArticleId><ArticleId IdType="pubmed">36364743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateu-de Antonio J., Florit-Sureda M. New Strategy to Reduce Hypertriglyceridemia During Parenteral Nutrition While Maintaining Energy Intake. J. Parenter. Enter. Nutr. 2016;40:705–712. doi: 10.1177/0148607114549253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0148607114549253</ArticleId><ArticleId IdType="pubmed">25214551</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>